Ryvu Therapeutics S.A. (WSE:RVU)

Market Cap	355.59M -51.2%
Revenue (ttm)	88.38M +92.8%
Net Income	-88.60M
EPS	-3.84
Shares Out	23.12M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	39,513
Open	15.60
Previous Close	15.40
Day's Range	15.20 - 15.68
52-Week Range	13.64 - 32.50
Beta	0.40
Analysts	Buy
Price Target	33.62 (+118.6%)
Earnings Date	May 21, 2026

About Ryvu Therapeutics

Ryvu Therapeutics S.A., a clinical-stage drug discovery and development company, engages in developing of small molecule therapies for treatment in oncology in Poland, European Union, and internationally. The company’s lead candidate, Romaciclib (RVU120), is a CDK8 and CDK19 kinase inhibitor in Phase 2 clinical trial with potential to treat monotheraphy, combination therapy, monotherapy, and myelofibrosis. It also develops Dapolsertib (SEL24/MEN1703), a dual PIM and FLT3 kinase inhibitor licensed to the Menarini Group that is in study start-up ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Employees: 228
• Stock Exchange: Warsaw Stock Exchange
• Ticker Symbol: RVU

Financial Performance

In 2025, Ryvu Therapeutics's revenue was 87.70 million, a decrease of -13.98% compared to the previous year's 101.96 million. Losses were -101.23 million, -9.16% less than in 2024.

Analyst Summary

According to 5 analysts, the average rating for RVU stock is "Buy." The 12-month stock price target is zł 33.62, which is an increase of 118.60% from the latest price.

Price Target

zł 33.62

(118.60% upside)

Analyst Consensus: Buy